Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Global Mass Spectrometry Market to Reach USD 10.78 Billion by 2031, Driven by Biologics, Precision Medicine and LC-MS/MS Adoption

globenewswire.com
TMO Thermo Fisher Scientific is a major player in the mass spectrometry market, which is experiencing significant growth driven by advancements in biologics, precision medicine, and AI integration. The company's instruments and solutions are well-positioned to benefit from increased demand in pharmaceutical, biotechnology, and clinical diagnostics. A Agilent Technologies is identified as a key company in the growing mass spectrometry market. The increasing adoption of advanced analytical systems, particularly LC-MS/MS, in pharmaceutical, biotech, and clinical research applications bodes well for Agilent's product portfolio and market position. BRKR Bruker Corporation is a significant participant in the mass spectrometry market, which is projected for substantial growth. The company's advanced hybrid systems are in demand for complex biologic characterization and other high-value applications, indicating a positive outlook.

Global Mass Spectrometry Market to Reach USD 10.78 Billion by 2031, Driven by Biologics, Precision Medicine and LC-MS/MS Adoption Dublin, Sept. 15, 2026 (GLOBE NEWSWIRE) -- "Mass Spectrometry Market by Product, Inlet Type, Application, End User - Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering.

The global mass spectrometry market is projected to grow from USD 7.07 billion in 2026 to USD 10.78 billion by 2031, registering a compound annual growth rate of 8.8% during the forecast period. Market expansion is being supported by precision medicine, biologics development, multi-omics research and regulatory-driven bioanalytical testing across pharmaceutical, biotechnology, clinical diagnostics, food safety and environmental applications.

Increasing adoption of high-resolution LC-MS/MS and hybrid mass spectrometry platforms is a key market trend. Laboratories are integrating these systems with artificial intelligence-enabled analytics, automation, cloud-connected workflows and robotic sample preparation to improve throughput, reproducibility and operational efficiency.

Pharmaceutical and biopharmaceutical companies continue to invest in advanced mass spectrometry systems for biomarker discovery, antibody-drug conjugate characterization, cell and gene therapy development and FDA-compliant pharmacokinetic analysis. Hospitals and diagnostic laboratories are also deploying benchtop clinical LC-MS/MS systems for endocrinology, toxicology and precision oncology testing. Additional growth is coming from outsourced bioanalytical services delivered by contract research organizations, rising PFAS and environmental contaminant testing, and the transition toward standardized, digitally integrated analytical ecosystems.

Instruments to retain the largest product share

By product, the mass spectrometry market is segmented into instruments, software and services. Instruments are projected to account for the largest market share during the forecast period, reflecting increased investment in advanced analytical technologies for pharmaceutical, biotechnology, clinical research and multi-omics applications.

Demand is being reinforced by increasingly complex drug development workflows involving biologics, antibody-drug conjugates, cell and gene therapies and precision medicine. Pharmaceutical and biopharmaceutical organizations are adopting next-generation platforms offering greater sensitivity, high-resolution analysis, automation and AI-enabled workflow capabilities to accelerate research, enhance bioanalytical efficiency and maintain regulatory compliance.

North America and Europe are experiencing faster instrument replacement and upgrade cycles as technological innovation encourages research laboratories, hospitals and clinical institutions to adopt high-throughput analytical systems.

LC-MS expected to dominate the inlet type segment

By inlet type, the market is segmented into GC-MS, LC-MS, ICP-MS and other inlet types. LC-MS is expected to hold the largest share due to widespread adoption in pharmaceutical and biotechnology research, clinical diagnostics, food safety and environmental testing. Segment growth is supported by regulatory acceptance, expanding biologics and precision medicine programs, and demand for advanced bioanalytical workflows.

Implementation of the ICH M10 bioanalytical method validation guidelines by the U.S. Food and Drug Administration and other international regulatory agencies has strengthened the role of LC-MS/MS in pharmacokinetic analysis, biomarker quantification and regulated drug testing. Pharmaceutical companies and CROs are consequently increasing investments in next-generation LC-MS/MS systems for clinical development, regulatory compliance and high-throughput drug analysis.

Pharma and biopharma manufacturing leads application demand

The pharma and biopharma manufacturing application segment accounted for the largest share of the mass spectrometry market. Adoption is increasing across drug discovery, biologics characterization, biomarker identification and GMP-compliant quality control. Advanced LC-MS/MS and high-resolution mass spectrometry systems are supporting the development of complex biologics, antibody-drug conjugates, peptides, biosimilars, and cell and gene therapies.

Precision medicine, impurity profiling, regulatory compliance and real-time process monitoring are expanding the use of mass spectrometry throughout pharmaceutical research, development and manufacturing. Growth in proteomics, metabolomics, omics research and personalized medicine is also encouraging product innovation, including automated, high-throughput and AI-enabled systems for translational research and biopharmaceutical workflows.

Outsourcing of bioanalytical testing to CROs and contract development and manufacturing organizations, combined with investment in biologics and advanced therapies, is further strengthening pharmaceutical and biotechnology demand. These trends position pharma and biopharma among the fastest-growing and highest-revenue-generating mass spectrometry applications.

Pharmaceutical companies represent the leading end-user segment

End users include pharmaceutical companies, biotechnology companies, research laboratories and academic institutes, environmental testing laboratories, the food and beverage industry, hospital clinical and forensic laboratories, the petrochemical industry and other organizations. Pharmaceutical companies are projected to account for the largest share and register the fastest growth during the forecast period, driven by biologics development, precision therapeutics and multi-omics-based drug discovery.

Advanced hybrid systems-including Orbitrap, Q-TOF, Triple Quadrupole Linear Ion Trap and FT-MS platforms-are increasingly being deployed for complex biologic characterization, antibody-drug conjugate analysis, host-cell protein monitoring and real-time process analytical technology applications. Manufacturers are integrating high-resolution hybrid systems into production, quality control and bioanalytical environments to support continuous bioprocessing, impurity profiling, glycosylation studies and ultra-trace contaminant detection.

This trend is particularly significant in monoclonal antibody, mRNA and cell therapy manufacturing facilities, where next-generation therapeutic programs require highly sensitive, high-resolution analytical capabilities.

Asia Pacific projected to record the highest regional growth rate

The report covers North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Asia Pacific is projected to achieve the highest growth rate as biologics manufacturing, multi-omics research, precision medicine and pharmaceutical outsourcing expand across China, India, Japan, South Korea and Southeast Asia.

CROs, CDMOs and biopharmaceutical manufacturers in the region are deploying high-resolution hybrid LC-MS/MS, Orbitrap and Q-TOF systems for biologic characterization, impurity profiling, glycan analysis, and cell and gene therapy workflows. Government investment in genomics, proteomics, metabolomics and translational medicine is also accelerating the adoption of AI-enabled and cloud-connected mass spectrometry platforms in research and clinical diagnostics.

Laboratory digitalization represents another major regional development. Robotic sample preparation, laboratory information system integration and automated bioanalytical workflows are being introduced to support high-throughput drug development and regulatory compliance. Asia Pacific's emergence as a global pharmaceutical and bioanalytical outsourcing hub is generating recurring demand for advanced LC-MS infrastructure among CROs and contract testing laboratories.

Competitive landscape

Major companies operating in the global mass spectrometry market include Thermo Fisher Scientific, Agilent Technologies, Sciex, Waters Corporation, Bruker and PerkinElmer Inc. in the United States, as well as Shimadzu Corporation in Japan, among others.

The primary participant profile used for the report comprises:

Research coverage

The research evaluates the mass spectrometry market by product, inlet type, application, end user and region. It examines market growth drivers, restraints, challenges and opportunities while assessing the competitive positions of established market leaders and small and medium-sized enterprises. Revenue estimates cover the overall market, individual segments, five major regions and related micro-markets.

The report is designed to help market leaders and new entrants evaluate revenue opportunities, understand competitive conditions, strengthen market positioning and develop effective go-to-market strategies. Coverage includes:

Key Attributes:

Key Topics Covered:

Market Dynamics Drivers

Challenges

Opportunities

Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/6xwpmd

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.